Acute heart failure in a patient treated by mitoxantrone for multiple slerosis;Insuffisance cardiaque aiguë chez une patiente traitée par mitoxantrone pour sclérose en plaques

Revue Neurologique

Volumn 159, Issue 12, 2003, Pages 1169-1172

  Feuillet, L ^a   Guedj, E ^a   Eusebio, A ^a   Malikova, I ^a   Pelletier, J ^a   Mundler, O ^a   Chérif, A Ali ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MITOXANTRONE;

ACUTE HEART FAILURE; ADULT; ARTICLE; CARDIOTOXICITY; CASE REPORT; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MULTIPLE SCLEROSIS; RECURRENT DISEASE;

ACUTE DISEASE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS;

EID: 1642430592     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. ALEXANDER J, DAINIAK N, BERGER HJ, et al. (1979). Serial assessment of doxorubicin cardiotoxicity with radionuclide angiocardiography. N Engl J Med, 300: 278-283.
2. CRISTOFANILLI M, HOLMES FA, ESPARZA L, VALERO V, BUZDAR AU, NEIDHART JA, HORTOBAGYI GN. (1999). Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Res Treat, 54: 225-233.
3. CROSSLEY RJ. (1984). Clinical safety and tolerance of mitoxantrone. Semin Oncol, 11: 54-58.
4. EDAN G, MILLER D, CLANET M, et al. (1997). Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry, 62: 112-118.
5. EDAN G et le Groupe Français d'Étude de la Mitoxantrone. (2001). Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients. Mult Scler, 7: S14.
6. EDAN G. (2001). Traitement des formes évolutives de SEP in Consensus Conference Organized by the French Federation for Neurology. Rev Neurol (Paris), 157: 1008-1013.
7. GONSETTE RE, DEMONTY L. (1990). Immunosuppresion with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology, 40: 261.
8. GONSETTE RE. (1996). Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler, 1: 329-332.
9. HARTUNG HP, GONSETTE R, KONIG N, et al. (2002). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet, 360: 2018-2025.
10. JAIN KK. (2000). Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Investig Drugs, 9: 1139-1149.
11. KAPPOS L, GOLD R, KUNSLER E, ROHRBACH E, HEUN R, STADT D, HOFMANN E. (1990). Mitoxantrone in the treatment of rapidly progressive MS: a pilot study with serial gadolinium enhanced MRI. Neurology, 40: 261.
12. th congress of European Committee for Treatment and Research In Multiple Sclerosis. Stockholm, Sweden.
13. KURTZKE JF. (1983). Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology, 33: 1444-1452.
14. MILLEFIORINI E, GASPERINI C, POZZILLI C, et al. (1997). Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol, 244: 153-159.
15. NOUSIAINEN T, VANNINEN E, JANTUNEN E, PUUSTINEN J, REMES J, RANTALA A, HARTIKAINEN J. (2001). Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy. J Intern Med, 2001, 249: 297-303.
16. OLINDO S, GUILLON B, HELIAS J, PHILLIBERT B, MAGNE C, FEVE JR. (2002). Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol, 9: 287-291.
17. PFISTERER ME, BATTLER A, ZARET BL. (1985). Range of normal values for left and right ventricular ejection fraction at rest and during exercise assessed by radionuclide angiocardiography. Eur Hearth J, 6: 647-655.
18. SEQUEIRA JF, MADRUGA IM, RIBEIRO M, DUARTE PC, FERREIRA DC, SARMENTO JL. (1994). The cardiac toxicity of cancer chemotherapy. Acta Med Port, 7: 311-318.
19. VAN DER GRAAF WT, DE VRIES EG. (1990). Mitoxantrone: bluebeard for malignancies. Anticancer Drugs, 1: 109-25.